Tools

Washington University investigators have created and validated several different measurement tools which OTM provides to the research community through licensing.

SNOT HEAR-QL AD8 CDR VarScan NEO YDR OSAKA SENSE

Assessment Licensing Information

The terms and conditions for licensing may be based on your

  • organization’s status as not-for-profit or for-profit entity,
  • research-funding status,
  • intended use of the assessment,
  • number of uses of the assessment, and
  • desired term of use of the assessment.

Below you will find the process to obtain the non-negotiable non-exclusive license agreement.

Process for obtaining a license:

  1. Review the information within table to obtain the correct agreement.
  2. Complete the non-negotiable agreement where indicated and return the document to the OTM Contact.
  3. The OTM Contact will review and either
    • begin the signature process, or
    • contact you to obtain further information.

For questions regarding licensing each particular assessment, please email the managing OTM Contact indicated within each section below.

SNOT 16, 20 and 22

The Sino-Nasal Outcome Test Assessments (SNOT 16, SNOT 20 and SNOT 22) are patient-based rhinosinusitis outcome measures.  Each SNOT Assessment contains questions concerning nasal blockage and a decreased sense of smell/taste, and each are a valid measure of rhinosinusitis health status and quality of life.

Please choose from the options below to obtain the correct agreement.  Please click here to email the completed agreement.  For questions regarding the SNOT Assessments, please contact Craig Weilbaecher.

HEAR-QL (Child or Adolescent)

The Hearing Environments and Reflection on Quality of Life Questionnaires (HEAR-QL) are condition-specific quality-of-life questionnaires designed to (a) determine how a child or adolescent perceives the effects of hearing loss, and (b) aid the clinician in determining where intervention is warranted to improve the child’s or adolescent’s overall being.

Please choose from the options below to obtain the correct agreement.  Please click here to email the completed agreement.  For questions regarding HEAR-QL, please contact Lidia Sobkow.

AD8™ Licensing

The AD8TM is a 5-point scale used to characterize six domains of cognitive and functional performance applicable to Alzheimer Disease and related dementias: memory, orientation, judgment & problem solving, community affairs, home & hobbies, and personal care.  The AD8TM feedback provides descriptive anchors that guide the clinician in making appropriate ratings based on interview data and clinical judgment.

Permission & Licensing Policy

Please select from one of the following options to obtain the appropriate agreement:

I will be using AD8TM for:

(1) patient care by a physician

(2) academic research that is NOT funded in-whole or in-part by a commercial entity

(3) clinical trials

If your use case is not listed, please email Scott Crick.

CDR™ Licensing

The CDRTM is a 5-point scale used to characterize six domains of cognitive and functional performance applicable to Alzheimer Disease and related dementias: memory, orientation, judgment & problem solving, community affairs, home & hobbies, and personal care.  The CDRTM feedback provides descriptive anchors that guide the clinician in making appropriate ratings based on interview data and clinical judgment.

Please select from one of the following options to obtain the appropriate agreement:

I will be using CDRTM for:

(1) patient care by a physician

(2) academic research that is NOT funded in-whole or in-part by a commercial entity

(3) clinical trials

If your use case is not listed, please email Scott Crick.

VarScan

VarScan is a Java-based, platform-independent software tool that can detect variants in next-generation sequencing (NGS) data. It employs a robust statistical approach to call variants and is able to handle; germline variants, multi-sample variants, somatic mutations and somatic copy number alterations.

In continuous development at the one of the world’s leading genome centers and with an ever growing community of users, VarScan remains the premium variant caller in the market.

The summaries of terms for a Non-Exclusive Agreement are given below.

  • Field: All uses, including research and commercial applications
  • Territory: Worldwide
  • Term: 3 years
  • License Issue Fee: $5,000 (fully creditable towards the 1st year Annual License Fee)
  • By the anniversary of Effective Date of each calendar year, Licensee shall provide WU with a written report specifying the number of Samples analyzed in the immediately preceding calendar year. Following receipt of such report from Licensee, WU shall issue an invoice to Licensee for applicable Annual License Fee.
  • Annual License Fee:VarScan Table

Sample: means any unique pair of sequence/reference comparison where a sequence of nucleic acids is compared to a reference using Software or Derivative Works of Software.  The reference may be a single sequence or collection of sequences.

Send the completed agreement to Scott Crick.

VarScan Non-Exclusive License Agreement

NEO Assessment

The Neonatal Eating Outcome (NEO) Assessment’s purpose is to assess age-appropriate oral motor and feeding skills in preterm infants prior to and at term equivalent age. A preview of the assessment can be found here.  This assessment attempts to gauge normal versus abnormal progression of feeding across differing postmenstrual ages (PMA), when lack of feeding success can be either a flag for abnormality or part of the normal process of maturation.  It can be used with breast or bottle fed infants. Scoring of the NEO is based on the infant’s PMA at the time of assessment.

To order a NEO Assessment, click here.  If the link does not work, copy and paste https://commerce.cashnet.com/NEO into your search bar.

The full assessment is appropriate for infants who have initiated oral feeding (approximately 30-32 weeks PMA) through approximately 4-6 weeks post-term. An abbreviated form can be used for infants after 30 weeks PMA who are not yet orally feeding.

For information on obtaining the NEO Assessment, please contact Jessica Roussin or Scott Crick.

YDR

Your Disease Risk (YDR) is one of the longest running, publicly available health risk assessments on the Internet. Launched in early 2000 and continually updated to the present time, the site offers risk assessments for twelve different cancers plus five other important chronic diseases: heart disease, stroke, diabetes, COPD, and osteoporosis.

Developed by chronic disease epidemiologist, Dr. Graham Colditz, MD, DrPH, Associate Director for Prevention and Control at Siteman Cancer Center, the WashU YDR website is conservatively estimated to have reached over 4 million unique visitors since its launch.  Over the past 12 months alone, it has hosted 250,000 unique visits, with 3.7 million page views.

Unique among most evidence-based assessments, YDR has a simple, straightforward interface. The assessment questions can be completed in a matter of minutes without any clinical data, and for each disease, the website offers both a visual and verbal risk estimate as well as personalized tips for prevention and lowering risk of disease.  In published validation studies, the tool has been found to provide well-calibrated estimates of cancer risk and heart disease risk relative to the general population.

WashU offers a non-negotiable, non-exclusive license to assessment wording and logic as well as risk calculation and population prevalence (US) spreadsheets for YDR.  Included under this license is documentation explaining the approach of the calculations and logic, as well as suggestions for potentially lowering your risk of certain diseases.

No software code or design elements are offered under this licensing mechanism.  Also, if support services are required, they can be arranged under a separate agreement.

Please use this non-negotiable, non-exclusive license agreement for non-commercial use of the YDR Tool(s).

For additional information or for commercial use of YDR, please contact Renatus Sinkeldam.

OSAKA

The Obstructive Sleep Apnea Knowledge and Attitudes (OSAKA) Questionnaires provide measures of a physician’s knowledge about and attitudes towards obstructive sleep apnea.  There are two versions of the OSAKA Questionnaire.  The OSAKA for adults is a 22-item measure and the OSAKA-KIDS for children is a 23-item measure.

Please choose from the options below to obtain the correct agreement for non-commercial use, which includes educational and research use, of the OSAKA for adults and/or the OSAKA-KIDS.

Please email the completed agreement to Scott Crick.  For questions regarding commercial use or funded research studies, please contact Scott Crick.

Supporting & Enhancing NICU Sensory Experiences (SENSE)

SENSE (Supporting and Enhancing NICU Sensory Experiences) is a comprehensive approach to ensuring multi-modal positive sensory exposures across hospitalization for high-risk infants in the NICU. The SENSE program provides education to engage families in providing developmentally appropriate positive sensory exposures to optimize outcomes for their infant(s). Topics of education include: medical terminology, fetal development in the final months of pregnancy, the sensory environment of the NICU, sensory development, reading infant cues, identifying readiness for sensory exposures, how to provide different sensory exposures, and a week-by-week guide* on specific doses and timing of sensory exposures to ensure consistent and developmentally appropriate delivery of positive sensory experiences at each postmenstrual age. The sensory interventions are designed to be provided by parents, but the medical team and/or volunteers can also be engaged to ensure the sensory needs of each infant are met.

To order the SENSE Intervention, click here.  If the link does not work, copy and paste https://commerce.cashnet.com/SENSE into your search bar.

In addition to the education materials and week-by-week guide, log sheets for parents, the medical team, and volunteers are provided to track the positive sensory exposures that are implemented each week. Although specific doses of positive sensory exposures are identified in the guide, it can be individualized for each infant based on the preferences of the family and/or the medical status/tolerance of the infant. An assessment of sensory tolerance is also included in the SENSE program package. This weekly infant assessment, which can be conducted more often when needed, aims to ensure that the infant tolerates the week-by week sensory exposures as described, and it also provides guidance on how to identify adaptations to sensory exposures when necessary. The weekly infant assessment is designed to be conducted by a physical or occupational therapist with neonatal expertise or by another designated health care professional.

Rationale: High-risk infants who receive care in the neonatal intensive care unit (NICU) are exposed to significant stressors that include painful procedures, disruption of normal sensory experiences, and stress related to parent-infant separation. There is growing concern that these alterations in the early environment, during a period of rapid brain development, can negatively impact developmental outcomes.

In an environment where stimuli are primarily negative, positive sensory exposures and parent-infant interaction are crucial and can have life-long implications on learning, memory, emotions, and developmental progression. It is well understood that multi-dimensional sensory exposures are present in utero in the final months and weeks of pregnancy, but an infant born preterm misses those potentially important, timed exposures that may be absent or altered in the NICU environment.

While the use of positive sensory exposures, such as massage, auditory exposure, and skin-to-skin care have been related to better parent and infant outcomes, a guideline that describes specific doses and targeted timing of positive multi-modal sensory exposures across all the days, weeks or months of hospitalization was needed. The SENSE program was developed to fill that need.

Applications: The SENSE program is a comprehensive, standardized guideline on providing developmentally appropriate and timed sensory exposures for preterm and high-risk infants who are hospitalized in the NICU. The guideline can be initiated immediately after birth and used throughout NICU hospitalization. Education materials are designed for the family. The weekly infant assessment is designed to be conducted by a physical or occupational therapist with neonatal expertise or other designated medical professional.

Advantages:

  • Descriptive and comprehensive education aimed at informing and engaging parents in providing developmentally appropriate sensory exposures to their infant(s).
  • Evidence-based week-by-week sensory interventions that adjust with postmenstrual age.
  • Materials that can be individualized based on the needs of each NICU.
  • The written materials available in the SENSE package include: a booklet for parents, log sheets to track sensory exposures, and a weekly infant assessment. An electronic version of SENSE is also available that enables education materials to be pushed to a personal computer, iPhone, or tablet. The electronic version has videos that demonstrate the described interventions.

Stage of Development: This SENSE program is currently being utilized in a randomized control trial at St. Louis Children’s Hospital. Additional revisions may be made upon the completion of the randomized control trial.

*The week-by-week guide was developed after a rigorous process of protocol development. This  included an integrative review that outlined 88 articles on sensory-based interventions (auditory, tactile, vestibular, visual, kinesthetic, and olfactory/gustatory) that were used with preterm infants to improve outcome, expert input from a multidisciplinary group of 108 health care professionals that defined sensory interventions implemented across different NICUs, 3 multidisciplinary focus groups that provided a critical review of the guidelines, and interviews with 20 parents of preterm infants who gave input on the feasibility of implementing the SENSE guideline in the NICU. The week-by-week guide ensures that the type and timing of different sensory exposures are tailored to infants based on their developmental needs. A pilot study of 30 preterm infants using the finalized SENSE protocol demonstrated feasibility and preliminary evidence of a positive impact on parent confidence. A randomized clinical trial, which will identify infant and parent outcomes longitudinally, is currently underway.

For more information, please contact Jessica Roussin or Craig Weilbaecher.